The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

AD5  -  Alzheimer disease 5

Homo sapiens

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of AD5


Psychiatry related information on AD5


High impact information on AD5


Chemical compound and disease context of AD5


Biological context of AD5


Anatomical context of AD5


Associations of AD5 with chemical compounds


Physical interactions of AD5


Enzymatic interactions of AD5


Co-localisations of AD5

  • While apolipoprotein E (ApoE) and beta-amyloid (A beta) co-localize in senile plaques in cortex and cerebellum in Alzheimer disease (AD), the A beta-positive, predominantly diffuse plaques in the striatum do not exhibit ApoE immunoreactivity regardless of disease duration [41].

Regulatory relationships of AD5


Other interactions of AD5


Analytical, diagnostic and therapeutic context of AD5


  1. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. Jordan, B.D., Relkin, N.R., Ravdin, L.D., Jacobs, A.R., Bennett, A., Gandy, S. JAMA (1997) [Pubmed]
  2. Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults. Kadotani, H., Kadotani, T., Young, T., Peppard, P.E., Finn, L., Colrain, I.M., Murphy, G.M., Mignot, E. JAMA (2001) [Pubmed]
  3. Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development. Babin, P.J., Thisse, C., Durliat, M., Andre, M., Akimenko, M.A., Thisse, B. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  4. Phenotyping of apolipoprotein E using immobilized pH gradient gels for one-dimensional and two-dimensional separations. Golaz, O., Sanchez, J.C., James, R.W., Hochstrasser, D.F. Electrophoresis (1995) [Pubmed]
  5. Genetic study of apolipoprotein E gene, alpha-1 antichymotrypsin gene in sporadic Parkinson disease. Tang, G., Xie, H., Xu, L., Hao, Y., Lin, D., Ren, D. Am. J. Med. Genet. (2002) [Pubmed]
  6. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. Slooter, A.J., Tang, M.X., van Duijn, C.M., Stern, Y., Ott, A., Bell, K., Breteler, M.M., Van Broeckhoven, C., Tatemichi, T.K., Tycko, B., Hofman, A., Mayeux, R. JAMA (1997) [Pubmed]
  7. Senile dementia with tangles (tangle predominant form of senile dementia). Jellinger, K.A., Bancher, C. Brain Pathol. (1998) [Pubmed]
  8. Donepezil therapy in clinical practice: a randomized crossover study. Greenberg, S.M., Tennis, M.K., Brown, L.B., Gomez-Isla, T., Hayden, D.L., Schoenfeld, D.A., Walsh, K.L., Corwin, C., Daffner, K.R., Friedman, P., Meadows, M.E., Sperling, R.A., Growdon, J.H. Arch. Neurol. (2000) [Pubmed]
  9. No association between a presenilin 1 polymorphism and Alzheimer disease. Romas, S.N., Mayeux, R., Tang, M.X., Lantigua, R., Medrano, M., Tycko, B., Knowles, J. Arch. Neurol. (2000) [Pubmed]
  10. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Goetz, C.G., Burke, P.F., Leurgans, S., Berry-Kravis, E., Blasucci, L.M., Raman, R., Zhou, L. Arch. Neurol. (2001) [Pubmed]
  11. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Bertram, L., McQueen, M.B., Mullin, K., Blacker, D., Tanzi, R.E. Nat. Genet. (2007) [Pubmed]
  12. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerrière, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., Dubas, F., Frebourg, T., Campion, D. Nat. Genet. (2006) [Pubmed]
  13. Presenilins Form ER Ca(2+) Leak Channels, a Function Disrupted by Familial Alzheimer's Disease-Linked Mutations. Tu, H., Nelson, O., Bezprozvanny, A., Wang, Z., Lee, S.F., Hao, Y.H., Serneels, L., De Strooper, B., Yu, G., Bezprozvanny, I. Cell (2006) [Pubmed]
  14. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Morgan, N.V., Westaway, S.K., Morton, J.E., Gregory, A., Gissen, P., Sonek, S., Cangul, H., Coryell, J., Canham, N., Nardocci, N., Zorzi, G., Pasha, S., Rodriguez, D., Desguerre, I., Mubaidin, A., Bertini, E., Trembath, R.C., Simonati, A., Schanen, C., Johnson, C.A., Levinson, B., Woods, C.G., Wilmot, B., Kramer, P., Gitschier, J., Maher, E.R., Hayflick, S.J. Nat. Genet. (2006) [Pubmed]
  15. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Zhou, B., Westaway, S.K., Levinson, B., Johnson, M.A., Gitschier, J., Hayflick, S.J. Nat. Genet. (2001) [Pubmed]
  16. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Ravaglia, G., Forti, P., Maioli, F., Martelli, M., Servadei, L., Brunetti, N., Porcellini, E., Licastro, F. Am. J. Clin. Nutr. (2005) [Pubmed]
  17. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Hogervorst, E., Ribeiro, H.M., Molyneux, A., Budge, M., Smith, A.D. Arch. Neurol. (2002) [Pubmed]
  18. Plasma phosphatidylcholine docosahexaenoic Acid content and risk of dementia and Alzheimer disease: the framingham heart study. Schaefer, E.J., Bongard, V., Beiser, A.S., Lamon-Fava, S., Robins, S.J., Au, R., Tucker, K.L., Kyle, D.J., Wilson, P.W., Wolf, P.A. Arch. Neurol. (2006) [Pubmed]
  19. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Evans, R.M., Hui, S., Perkins, A., Lahiri, D.K., Poirier, J., Farlow, M.R. Neurology (2004) [Pubmed]
  20. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. Pericak-Vance, M.A., Bass, M.P., Yamaoka, L.H., Gaskell, P.C., Scott, W.K., Terwedow, H.A., Menold, M.M., Conneally, P.M., Small, G.W., Vance, J.M., Saunders, A.M., Roses, A.D., Haines, J.L. JAMA (1997) [Pubmed]
  21. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, R.H., Pericak-Vance, M.A., Risch, N., van Duijn, C.M. JAMA (1997) [Pubmed]
  22. A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Olson, J.M., Goddard, K.A., Dudek, D.M. Am. J. Hum. Genet. (2002) [Pubmed]
  23. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., Roses, A.D. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  24. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Corder, E.H., Saunders, A.M., Risch, N.J., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Rimmler, J.B., Locke, P.A., Conneally, P.M., Schmader, K.E. Nat. Genet. (1994) [Pubmed]
  25. Familial dementia with lewy bodies: a clinical and neuropathological study of 2 families. Tsuang, D.W., Dalan, A.M., Eugenio, C.J., Poorkaj, P., Limprasert, P., La Spada, A.R., Steinbart, E.J., Bird, T.D., Leverenz, J.B. Arch. Neurol. (2002) [Pubmed]
  26. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Galasko, D., Chang, L., Motter, R., Clark, C.M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., Miller, B., Green, R., Basherad, R., Kertiles, L., Boss, M.A., Seubert, P. Arch. Neurol. (1998) [Pubmed]
  27. Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Barber, R., Gholkar, A., Scheltens, P., Ballard, C., McKeith, I.G., Morris, C.M., O'Brien, J.T. Arch. Neurol. (1999) [Pubmed]
  28. Apolipoprotein E and neuromuscular disease: a critical review of the literature. Bedlack, R.S., Strittmatter, W.J., Morgenlander, J.C. Arch. Neurol. (2000) [Pubmed]
  29. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. Small, G.W., Mazziotta, J.C., Collins, M.T., Baxter, L.R., Phelps, M.E., Mandelkern, M.A., Kaplan, A., La Rue, A., Adamson, C.F., Chang, L. JAMA (1995) [Pubmed]
  30. Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. Mahley, R.W., Weisgraber, K.H., Innerarity, T.L., Rall, S.C. JAMA (1991) [Pubmed]
  31. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. Morris, M.C., Evans, D.A., Bienias, J.L., Tangney, C.C., Bennett, D.A., Aggarwal, N., Wilson, R.S., Scherr, P.A. JAMA (2002) [Pubmed]
  32. Dietary intake of antioxidants and risk of Alzheimer disease. Engelhart, M.J., Geerlings, M.I., Ruitenberg, A., van Swieten, J.C., Hofman, A., Witteman, J.C., Breteler, M.M. JAMA (2002) [Pubmed]
  33. Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease. Mooser, V., Helbecque, N., Miklossy, J., Marcovina, S.M., Nicod, P., Amouyel, P. Ann. Intern. Med. (2000) [Pubmed]
  34. The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR. Masselink, H., Bernards, R. Oncogene (2000) [Pubmed]
  35. The Alzheimer disease-related calcium-binding protein Calmyrin is present in human forebrain with an altered distribution in Alzheimer's as compared to normal ageing brains. Bernstein, H.G., Blazejczyk, M., Rudka, T., Gundelfinger, E.D., Dobrowolny, H., Bogerts, B., Kreutz, M.R., Kuznicki, J., Wojda, U. Neuropathol. Appl. Neurobiol. (2005) [Pubmed]
  36. Basic fibroblast growth factor binding is a marker for extracellular neurofibrillary tangles in Alzheimer disease. Siedlak, S.L., Cras, P., Kawai, M., Richey, P., Perry, G. J. Histochem. Cytochem. (1991) [Pubmed]
  37. E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53. Wienzek, S., Roth, J., Dobbelstein, M. J. Virol. (2000) [Pubmed]
  38. Biochemical analysis of adenovirus type 5 DNA-binding protein mutants. Neale, G.A., Kitchingman, G.R. J. Biol. Chem. (1989) [Pubmed]
  39. Alzheimer Disease-specific Conformation of Hyperphosphorylated Paired Helical Filament-Tau Is Polyubiquitinated through Lys-48, Lys-11, and Lys-6 Ubiquitin Conjugation. Cripps, D., Thomas, S.N., Jeng, Y., Yang, F., Davies, P., Yang, A.J. J. Biol. Chem. (2006) [Pubmed]
  40. Phosphorylation at the carboxy terminus of the 55-kilodalton adenovirus type 5 E1B protein regulates transforming activity. Teodoro, J.G., Halliday, T., Whalen, S.G., Takayesu, D., Graham, F.L., Branton, P.E. J. Virol. (1994) [Pubmed]
  41. Astrocyte-apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study. Shao, Y., Gearing, M., Mirra, S.S. J. Neuropathol. Exp. Neurol. (1997) [Pubmed]
  42. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. Saunders, A.M. J. Neuropathol. Exp. Neurol. (2000) [Pubmed]
  43. The role of TNF and its receptors in Alzheimer's disease. Perry, R.T., Collins, J.S., Wiener, H., Acton, R., Go, R.C. Neurobiol. Aging (2001) [Pubmed]
  44. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Prince, J.A., Feuk, L., Gu, H.F., Johansson, B., Gatz, M., Blennow, K., Brookes, A.J. Hum. Mutat. (2003) [Pubmed]
  45. Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics. Espeseth, A.S., Xu, M., Huang, Q., Coburn, C.A., Jones, K.L., Ferrer, M., Zuck, P.D., Strulovici, B., Price, E.A., Wu, G., Wolfe, A.L., Lineberger, J.E., Sardana, M., Tugusheva, K., Pietrak, B.L., Crouthamel, M.C., Lai, M.T., Dodson, E.C., Bazzo, R., Shi, X.P., Simon, A.J., Li, Y., Hazuda, D.J. J. Biol. Chem. (2005) [Pubmed]
  46. Interaction between presenilin 1 and ubiquilin 1 as detected by fluorescence lifetime imaging microscopy and a high-throughput fluorescent plate reader. Thomas, A.V., Herl, L., Spoelgen, R., Hiltunen, M., Jones, P.B., Tanzi, R.E., Hyman, B.T., Berezovska, O. J. Biol. Chem. (2006) [Pubmed]
  47. No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese. Lee, D.W., Liu, H.C., Liu, T.Y., Chi, C.W., Hong, C.J. Am. J. Med. Genet. (2000) [Pubmed]
  48. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y., Dong, L.M., Salvesen, G.S., Pericak-Vance, M., Schmechel, D., Saunders, A.M., Goldgaber, D., Roses, A.D. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  49. The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. Dermaut, B., Theuns, J., Sleegers, K., Hasegawa, H., Van den Broeck, M., Vennekens, K., Corsmit, E., St George-Hyslop, P., Cruts, M., van Duijn, C.M., Van Broeckhoven, C. Am. J. Hum. Genet. (2002) [Pubmed]
  50. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between {beta}-amyloid production and tau phosphorylation in Alzheimer disease. Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., Tabara, Y., Miki, T., Akatsu, H., Kosaka, K., Funakoshi, E., Nishitomi, K., Sakaguchi, G., Kato, A., Hattori, H., Uema, T., Takeda, M. Hum. Mol. Genet. (2007) [Pubmed]
  51. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. Weeber, E.J., Beffert, U., Jones, C., Christian, J.M., Forster, E., Sweatt, J.D., Herz, J. J. Biol. Chem. (2002) [Pubmed]
  52. The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study. Bergem, A.L., Engedal, K., Kringlen, E. Arch. Gen. Psychiatry (1997) [Pubmed]
  53. Genetic dissection of Alzheimer disease, a heterogeneous disorder. Schellenberg, G.D. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  54. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Poirier, J., Delisle, M.C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., Gilfix, B.M., Gauthier, S. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  55. Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. Gearing, M., Rebeck, G.W., Hyman, B.T., Tigges, J., Mirra, S.S. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
WikiGenes - Universities